Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Oncology. 2008;74(1-2):1-6. doi: 10.1159/000138349. Epub 2008 Jun 9.

The promise and perils of 'targeted therapy' of advanced ovarian cancer.

Author information

  • University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. mmarkman@mdanderson.org

Abstract

For several reasons, ovarian cancer is an excellent malignancy to consider the use of 'targeted' therapeutic strategies. However, to date, despite considerable effort, there remains limited evidence that such approaches are clinically relevant in the malignancy. The one important exception is the delivery of anti-angiogenic anti-neoplastic agents, which actually appear to be more biologically active as single drugs in ovarian cancer than in other solid tumors where they have been examined. It is anticipated that future trials of 'targeted' therapy in ovarian cancer will focus on molecular targets of documented relevance in the malignancy.

Copyright 2008 S. Karger AG, Basel.

PMID:
18536523
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Write to the Help Desk